Gene-regulating compositions and methods for improved immunotherapy
The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.
1. A method of treating cancer in a human subject comprising:
administering to the human subject a modified human tumor infiltrating lymphocyte (TIL) comprising a modified endogenous ZC3H12A gene, wherein
ZC3H12A protein expression and/or function is reduced in the modified human TIL, relative to ZC3H12A protein expression and/or function in an unmodified human TIL expressing an unmodified endogenous ZC3H12A gene, and
anti-tumor efficacy of the modified human TIL is increased, relative to anti-tumor efficacy of the unmodified human TIL.
2. The method of claim 1 , wherein the modified endogenous ZC3H12A gene comprises an insertion and deletion (indel).
3. The method of claim 1 , wherein the modified human TIL further comprises an exogenous transgene expressing an immune activating molecule selected from the group consisting of a cytokine, a chemokine, a co-stimulatory molecule, an activating peptide, and an antibody or an antigen-binding fragment thereof.
4. The method of claim 1 , wherein the modified human TIL further comprises a modified endogenous target gene selected from the group consisting of IKZF1, IKZF3, GATA3, BCL3, TNIP1, TNFAIP3, NFKBIA, SMAD2, TGFBR1, TGFBR2, TANK, FOXP3, RC3H1, TRAF6, IKZF2, CBLB, PPP2R2D, NRP1, HAVCR2, LAG3, TIGIT, CTLA4, PTPN6, PDCD1, BCOR, BCL2L11, FLI1, CALM2, DHODH, UMPS, RBM39, SEMA7A, CHIC2, PCBP1, PBRM1, WDR6, E2F8, SERPINA3, GNAS, MAP4K1 and NR4A3.
5. The method of claim 1 , wherein the modified human TIL further comprises a modified endogenous TGFBR2 gene.
6. The method of claim 5 , wherein the modified endogenous TGFBR2 gene comprises an indel.
7. The method of claim 1 , wherein the cancer is a leukemia, a lymphoma, or a solid tumor.
8. The method of claim 7 , wherein the cancer is a solid tumor.
9. The method of claim 8 , wherein the solid tumor is a melanoma, a pancreatic tumor, a bladder tumor, a lung tumor, a colorectal cancer, or a head and neck tumor.
10. The method of claim 9 , wherein the solid tumor is a melanoma.
11. The method of claim 1 , wherein the cancer is a PD1 resistant or PD1 insensitive cancer.
12. The method of claim 1 , wherein the modified human TIL is autologous to the human subject.
13. The method of claim 1 , wherein the modified human TIL is allogeneic to the human subject.
14. The method of claim 1 , wherein the modified human TIL is administered to the subject by infusion.
15. A method of treating cancer in a human subject comprising:
administering to the human subject a population of at least 1×10 6 modified human tumor infiltrating lymphocytes (TIL), wherein modified human TIL of the population comprise a modified endogenous ZC3H12A gene, wherein
the modified endogenous ZC3H12A gene comprises an insertion and deletion (indel),
ZC3H12A protein expression and/or function is reduced in the modified human TIL, relative to ZC3H12A protein expression and/or function in an unmodified human TIL expressing an unmodified endogenous ZC3H12A gene, and
anti-tumor efficacy of the modified human TIL is increased, relative to anti-tumor efficacy of the unmodified human TIL.
16. The method of claim 15 , wherein the cancer is a solid tumor.
17. The method of claim 16 , wherein the solid tumor is a melanoma.
18. The method of claim 15 , wherein the modified human TIL is autologous to the human subject.
19. The method of claim 15 , wherein the modified human TIL is administered to the subject by infusion.
20. The method of claim 15 , wherein the population comprises about 1×10 7 to about 1×10 12 of the modified human TIL.